Effect of the STAT3 inhibitor STX-0119 on the proliferation of a temozolomide-resistant glioblastoma cell line

International Journal of Oncology

Volumn 45, Issue 1, 2014, Pages 411-418

  Ashizawa, Tadashi ^a   Akiyama, Yasuto ^a   Miyata, Haruo ^a   Iizuka, Akira ^a   Komiyama, Masaru ^a   Kume, Akiko ^a   Omiya, Maho ^a   Sugino, Takashi ^a   Asai, Akira ^b   Hayashi, Nakamasa ^a   Mitsuya, Koichi ^a   Nakasu, Yoko ^a   Yamaguchi, Ken ^a  

^a SHIZUOKA CANCER CENTER   (Japan)

^b UNIVERSITY OF SHIZUOKA   (Japan)

Author keywords

Glioblastoma; Signal transducer and activator of transcription 3 inhibitor; Temozolomide resistance; YKL 40

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; PROTEIN INHIBITOR; STAT3 PROTEIN; STX 0119; TEMOZOLOMIDE; UNCLASSIFIED DRUG; DACARBAZINE; OXADIAZOLE DERIVATIVE; QUINOLINE DERIVATIVE; STAT3 PROTEIN, HUMAN; STX-0119;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; GENE EXPRESSION PROFILING; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; IC 50; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR INVASION; TUMOR RECURRENCE; TUMOR VOLUME; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; EPITHELIAL MESENCHYMAL TRANSITION; EXPERIMENTAL NEOPLASM; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DACARBAZINE; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; MALE; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASMS, EXPERIMENTAL; OXADIAZOLES; QUINOLINES; STAT3 TRANSCRIPTION FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84902583299     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2439     Document Type: Article

References (35)

1. Zhong Z, Wen L and Darnell JE Jr: Stat3 and Stat4: members of the family of signal transducers and activators of transcription. Proc Natl Acad Sci USA 91: 4806-4810, 1994.
2. Bromberg J and Darnell JE Jr: The role of STATs in transcriptional control and their impact on cellular functions. Oncogene 19: 2468-2473, 2000.
3. Yu H, Kortylewski M and Pardoll D: Crosstalk between cancer and immune cells: role of STAT3 in the tumor microenvironment. Nat Rev Immunol 7: 41-51, 2007.
4. Wang T, Niu G, Kortylewski M, et al: Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 10: 48-54, 2004.
5. Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005.
6. Mirimanoff RO, Gorlia T, Mason W, et al: Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol 24: 2563-2569, 2006.
7. Brennan C, Momota H, Hambardzumyan D, Ozawa T, Tandon A, Pedraza A and Holland E: Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS One 4: e7752, 2009.
8. Cheng CK, Fan QW and Weiss WA: PI3K signaling in glioma-animal models and therapeutic challenges. Brain Pathol 19: 112-120, 2009.
9. Demuth T, Reavie LB, Rennert JL, et al: MAP-ing glioma invasion: mitogen-activated protein kinase 3 and p38 drive glioma invasion and progression and predict patient survival. Mol Cancer Ther 6: 1212-1222, 2007.
10. Pu P, Zhang Z, Kang C, Jiang R, Jia Z, Wang G and Jiang H: Downregulation of Wnt2 and beta-catenin by siRNA suppresses malignant glioma cell growth. Cancer Gene Ther 16: 351-361, 2009.
11. Purow BW, Haque RM, Noel MW, et al: Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation. Cancer Res 65: 2353-2363, 2005.
12. Hegi ME, Diserens AC, Gorlia T, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352: 997-1003, 2005.
13. Murat A, Migliavacca E, Gorlia T, et al: Stem cell-related 'self-renewal' signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol 26: 3015-3024, 2008.
14. Hunter C, Smith R, Cahill DP, et al: A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res 66: 3987-3991, 2006.
15. Mukherjee B, McEllin B, Camacho CV, et al: EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma. Cancer Res 69: 4252-4259, 2009.
16. Ashizawa T, Miyata H, Ishii H, et al: Antitumor activity of a novel small molecules STAT3 inhibitor against a human lymphoma cell line with high STAT3 activation. Int J Oncol 38: 1245-1252, 2011.
17. Vlachostergios PJ, Hatzidaki E, Befani CD, Liakos P and Papandreau CN: Bortezomib overcomes MGMT-related resistance of glioblastoma cell lines to temozolomide in a schedule-dependent manner. Invest New Drugs 31: 1169-1181, 2013.
18. Jiang G, Wei ZP, Pei DS, Xin Y, Liu YQ and Zheng JN: A novel approach to overcome temozolomide resistance in glioma and melanoma: Inactivation of MGMT by gene therapy. Biochem Biophys Res Commun 406: 311-314, 2011.
19. Li GH, Wei H, Lv SQ, Ji H and Wang DL: Knockdown of STAT3 expression by RNAi suppresses growth and induces apoptosis and differentiation in glioblastoma stem cells. Int J Oncol 37: 103-110, 2010.
20. See AP, Han JE, Phallen J, et al: The role of STAT3 activation in modulating the immune microenvironment of GBM. J Neurooncol 110: 359-368, 2012.
21. Sherry MM, Reeves A, Wu JK and Cochran BH: STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells. Stem Cells 27: 2383-2392, 2009.
22. Liu Y, Li C and Lin J: STAT3 as a therapeutic target for glioblastoma. Anticancer Agents Med Chem 10: 512-519, 2010.
23. Jackson C, Ruzevick J, Amin AG and Lim M: Potential role for STAT3 inhibitors in glioblastoma. Neurosurg Clin N Am 23: 379-389, 2012.
24. Ashizawa T, Miyata H, Iizuka A, et al: Effect of the STAT3 inhibitor STX-0119 on the proliferation of cancer stem-like cells derived from recurrent glioblastoma. Int J Oncol 43: 219-227, 2013.
25. Kohsaka S, Wang L, Yachi K, et al: STAT3 inhibition overcomes temozolomide resistance in glioblastoma by donregulating MGMT expression. Mol Cancer Ther 11: 1289-1299, 2012.
26. Villalva C, Martin-Lanneree S, Cortes U, et al: STAT3 is essential for the maintenance of neurosphere-initiating tumor cells in patients with glioblastomas: a potential for targeted therapy? Int J Cancer 128: 826-838, 2011.
27. Pistollato F, Abbadi S, Rampazzo E, et al: Intratumoral hypoxic gradient drives stem cells distribution and MGMT expression in glioblastoma. Stem Cells 28: 851-862, 2010.
28. Yuki K, Natsume A, Yokoyama H, et al: Induction of oligodendrogenesis in glioblastoma-initiating cells by IFN-mediated activation of STAT3 signaling. Cancer Lett 284: 71-79, 2009.
29. Yoshino A, Ogino A, Yachi K, et al: Effect of IFN-β on human glioma cell lines with temozolomide resistance. Int J Oncol 35: 139-148, 2009.
30. Motomura K, Natsume A, Kishida Y, et al: Benefits of interferon-β and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter: A multicenter study. Cancer 117: 1721-1730, 2011.
31. Senft C, Priester M, Polacin M, Schroder K, Seifert V, Kogel D and Weissenberger J: Inhibition of the JAK-2/STAT3 signaling pathway impedes the migratory and invasive potential of human glioblastoma cells. J Neurooncol 101: 393-403, 2011.
32. Stechishin OD, Luchman HA, Ruan Y, et al: On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells. Neuro Oncol 15: 198-207, 2013.
33. Senft C, Polacin M, Priester M, Seifert V, Kogel D and Weissenberger J: The nontoxic natural compound Curcumin exerts anti-proliferative, anti-migratory, and anti-invasive properties against malignant gliomas. BMC Cancer 10: 491, 2010.
34. Yoshino A, Ogino A, Yachi K, et al: Gene expression profiling predicts response to temozolomide in malignant gliomas. Int J Oncol 36: 1367-1377, 2010.
35. Johnson BE, Mazor T, Hong C, et al: Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science 343: 189-193, 2013.